PCNU in the treatment of recurrent medulloblastoma and ependymoma--a POG Study.
Seventeen children with recurrent medulloblastoma and ependymoma received PCNU (100 mg/m2) in a Phase II trial. Response was evaluated by CAT scan. There were no responses. Administration of PCNU was associated with significant thrombocytopenia.